O TYM ODCINKU
In this session recorded at CMO Summit 2022, the panel discusses:
What CMOs need to know about series funding, crossover and IPOHow to think about when to engage in these financing options based on the company stage, milestones, and budgetHow CMOs can best support the decision-making and fundraising processes
Speakers:
Nerissa Kreher, MD, MBA, CMO, Entrada TherapeuticsGeoff Meyerson, MBA, Co-Founder & CEO, Locust WalkTariq Kassum, MD, CEO, Celsius TherapeuticsAnn Barbier, MD, PhD, CMO, CAMP4 Therapeutics
What CMOs need to know about series funding, crossover and IPOHow to think about when to engage in these financing options based on the company stage, milestones, and budgetHow CMOs can best support the decision-making and fundraising processes
Speakers:
Nerissa Kreher, MD, MBA, CMO, Entrada TherapeuticsGeoff Meyerson, MBA, Co-Founder & CEO, Locust WalkTariq Kassum, MD, CEO, Celsius TherapeuticsAnn Barbier, MD, PhD, CMO, CAMP4 Therapeutics
Język angielski
Stany Zjednoczone
TRANSKRYPCJA 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
WYSZUKAJ MINIONE ODCINKI
Wyszukaj minione odcinki PharmaTalkRadio.
INNE ODCINKI W TYM PODCASCIE
For more information, visit theconferenceforum.org
For more information, visit theconferenceforum.org
As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed.
In this podcast, Anil Diwan, President and Executive Chairman of NanoViricides Incorporated, explains some of the shortcomings of the current model of antiviral drug deve…
For more information, go to theconferenceforum.org
For more information, visit theconferenceforum.org
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z Pharma Talk Radio, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
